Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9459932 | 0.82 | CA1 (0.39) | SMN1; SMN2ACHEHTTCA1CA2 | |
| SCHEMBL19874869 | 0.80 | SMN1; SMN2 (0.37) | SMN1; SMN2ACHEHTTCA1CA2 | |
| SCHEMBL19874842 | 0.80 | SMN1; SMN2 (0.37) | SMN1; SMN2ACHEHTTCA1CA2 | |
| SCHEMBL9059001 | 0.77 | CA1 (0.35) | SMN1; SMN2ACHEHTTCA1CA2 | |
| SCHEMBL9370544 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2CA1CA2CA14CA12 | |
| SCHEMBL3140450 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2ACHEHTTCA1CA2 | |
| SCHEMBL7814071 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2CA1CA2CA14CA12 | |
| SCHEMBL1241162 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2ACHEHTTCA1CA2 | |
| SCHEMBL6762809 | 0.75 | ALDH1A1 (0.46) | HTTCA1CA2CA12KMT2A | |
| SCHEMBL9363946 | 0.75 | TSHR (0.40) | HTTCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1455663-A | Novel aerosol formulation containing polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | CN | claimed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2024-06-25 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2023-10-05 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| EP-4161936-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115867556-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-03-28 | — | — | CN | disclosed |
| US-11530189-B2 | Carbamate compounds and methods of making and using same | H. LUNDBECKA/S (DK) | 2022-12-20 | — | — | US | disclosed |
| CN-107982266-B | Carbamate compounds and methods of making and using the same | H.隆德贝克有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-1658871-A | Amide derivatives as GK activators | NOVO NORDISK AS (DK) | 2005-08-24 | — | — | CN | disclosed |
| CN-1455663-A | Novel aerosol formulation containing polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | CN | disclosed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | disclosed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| JP-2003040836-A | METHOD FOR PRODUCING METHYL 3,3,3-TRIFLUORO-2- HYDROXYPROPIONATE DERIVATIVE | CENTRAL GLASS CO LTD | 2003-02-13 | — | — | JP | disclosed |
| JP-2003040836-A | METHOD FOR PRODUCING METHYL 3,3,3-TRIFLUORO-2- HYDROXYPROPIONATE DERIVATIVE | CENTRAL GLASS CO LTD | 2003-02-13 | — | — | JP | disclosed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
| US-4107329-A | Fluorinated compounds as therapeutics | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530189-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | SMN1; SMN2 2374/4885ACHE 92/4885HTT 2200/4885 |
| US-20230312499-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, RABL6 | SMN1; SMN2 2374/4885ACHE 92/4885HTT 2200/4885 |
| US-12018004-B2 | Carbamate compounds and methods of making and using same | ABHD6, ABHD16A, RABL6 | SMN1; SMN2 2374/4885ACHE 92/4885HTT 2200/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | SMN1; SMN2 3539/4885ACHE 4867/4885HTT 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.